Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites
Objective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 pat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Perspectives in Clinical Research |
Subjects: | |
Online Access: | http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=Mehta |
id |
doaj-ae28b25ae8a44984a9279d38d529e7e7 |
---|---|
record_format |
Article |
spelling |
doaj-ae28b25ae8a44984a9279d38d529e7e72020-11-24T23:57:10ZengWolters Kluwer Medknow PublicationsPerspectives in Clinical Research2229-34852013-01-014421121410.4103/2229-3485.120169Feasibility study of clinical trial for breast cancer and lung cancer at Indian sitesVarun M MehtaArun D BhattObjective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 patients per month, frequency of Ethics Committee (EC) meeting ≤4 weeks, dropout rate <20%, adequacy of infrastructure and training of site in good clinical practice (GCP). Descriptive analyses of the data were performed. Results: For both indications, 50/300 (16.7%) sites responded. The median number of patients seen by a site per month for breast and lung cancer was 20 (range 0-300) and 10 (range 0-75), respectively. Median number of eligible patients was 4 (range 0-20) and 3 (range 0-15) per month, for breast and lung cancer respectively. The frequency of EC meeting was ≤4 weeks at 36-56% of sites. All sites were trained in GCP and had adequate infrastructure to conduct the clinical trial. For breast cancer 22 (44%) sites (public 14 [28%]; private 8 [16%)]), and for lung cancer 18 (36%) sites (public 15 [30%], private: 3 [6%]) met the criteria of selection. Conclusion: Preliminary feasibility study would require for confirmation of the important feasibility criteria by in depth discussion during the personal visit to the potential sites.http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=MehtaBreast cancerfeasibility studylung cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Varun M Mehta Arun D Bhatt |
spellingShingle |
Varun M Mehta Arun D Bhatt Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites Perspectives in Clinical Research Breast cancer feasibility study lung cancer |
author_facet |
Varun M Mehta Arun D Bhatt |
author_sort |
Varun M Mehta |
title |
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites |
title_short |
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites |
title_full |
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites |
title_fullStr |
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites |
title_full_unstemmed |
Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites |
title_sort |
feasibility study of clinical trial for breast cancer and lung cancer at indian sites |
publisher |
Wolters Kluwer Medknow Publications |
series |
Perspectives in Clinical Research |
issn |
2229-3485 |
publishDate |
2013-01-01 |
description |
Objective: The objective of this study was to conduct feasibility study of phase III breast and lung cancer clinical trials in India. Materials and Methods: Study synopsis and feasibility questionnaire were mailed to 300 oncologists for each indication. Criteria of selection were enrolment of ≥2 patients per month, frequency of Ethics Committee (EC) meeting ≤4 weeks, dropout rate <20%, adequacy of infrastructure and training of site in good clinical practice (GCP). Descriptive analyses of the data were performed. Results: For both indications, 50/300 (16.7%) sites responded. The median number of patients seen by a site per month for breast and lung cancer was 20 (range 0-300) and 10 (range 0-75), respectively. Median number of eligible patients was 4 (range 0-20) and 3 (range 0-15) per month, for breast and lung cancer respectively. The frequency of EC meeting was ≤4 weeks at 36-56% of sites. All sites were trained in GCP and had adequate infrastructure to conduct the clinical trial. For breast cancer 22 (44%) sites (public 14 [28%]; private 8 [16%)]), and for lung cancer 18 (36%) sites (public 15 [30%], private: 3 [6%]) met the criteria of selection. Conclusion: Preliminary feasibility study would require for confirmation of the important feasibility criteria by in depth discussion during the personal visit to the potential sites. |
topic |
Breast cancer feasibility study lung cancer |
url |
http://www.picronline.org/article.asp?issn=2229-3485;year=2013;volume=4;issue=4;spage=211;epage=214;aulast=Mehta |
work_keys_str_mv |
AT varunmmehta feasibilitystudyofclinicaltrialforbreastcancerandlungcanceratindiansites AT arundbhatt feasibilitystudyofclinicaltrialforbreastcancerandlungcanceratindiansites |
_version_ |
1725455298414510080 |